SCTC21C

Phase 3Biologic

SSinocelltech Ltd.

SCTC21C is one of 127 biologic programs targeting Hematologic Malignancies. It is currently in Phase 3.

Indications

Total Trials

Active Trials

126

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematologic MalignanciesRecruiting

AmyloidosisRecruiting

Multiple MyelomaRecruiting

Autoimmune DiseaseNot yet recruiting

Hematologic MalignanciesPhase 1

Recruiting

AmyloidosisPhase 3

Recruiting

Multiple MyelomaPhase 3

Recruiting

Autoimmune DiseasePhase 2

Not yet recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

TALVEY

Johnson & Johnson

Phase 3

24 3

Keytruda

Merck & Co.

Phase 3

17 4

Biaxin

AbbVie

Phase 3

15 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 6

Opdivo

Bristol-Myers Squibb

Phase 3

11 7

Cytosar

Teva

Phase 3

4 8

Mozobil

GGenzyme, a Sanofi Company

Phase 3

15 9

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Hematologic Malignancies

NCT06252298

Q4 2028

Phase 3Recruiting

Multiple Myeloma

NCT07297329

Phase 3Recruiting

Amyloidosis

NCT07388602

Q1 2029

Phase 1/2Not yet recruiting

Autoimmune Disease

NCT06774664

Clinical

Trials by Indication[1]

Autoimmune Disease1 trial

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Not yet recruiting·SSinocelltech Ltd.·Phase 1/2·NCT06774664·99 enrolled

Hematologic Malignancies1 trial

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Recruiting·SSinocelltech Ltd.·Phase 1·NCT06252298·74 enrolled

Multiple Myeloma1 trial

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07297329·292 enrolled

Amyloidosis1 trial

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Recruiting·SSinocelltech Ltd.·Phase 3·NCT07388602·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for SCTC21C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCTC21C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCTC21C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinocelltech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: SSinocelltech Ltd.

SCTC21C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Q1 2029

Trials by Indication[1]

Autoimmune Disease1 trial

Hematologic Malignancies1 trial

Multiple Myeloma1 trial

Amyloidosis1 trial

References

Drug Info

Quick Facts

Related News